us bitcoins- Top Related searches

Puli Pharmaceutical Co., Ltd.: It won the bid for the tenth batch of national centralized drug procurement. According to Puli Pharmaceutical, on December 12, Puli Pharmaceutical's meglumine gadolinium tetate injection (trade name: Puli Yingxian) and Posaconazole injection (trade name: Puli Posa) both won the bid for the tenth batch of national centralized drug procurement.Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Yingli shares: Yingli shares increased capital by 80 million yuan to its holding subsidiary. Yingli shares announced that the company and Shanghai Moqin Intelligent Technology Co., Ltd. increased capital to Nanchang Yingli Precision Manufacturing Co., Ltd., with a total capital increase of 80 million yuan, of which Yingli shares increased capital by 67 million yuan in cash and Shanghai Moqin increased capital by 13 million yuan in cash. After this capital increase, the registered capital of Nanchang Yingli will increase from 20 million yuan to 100 million yuan. After the capital increase is completed, Yingli shares hold 80% of the shares of Nanchang Yingli and Shanghai Moqin holds 20% of the shares. This capital increase does not constitute a connected transaction and does not need to be submitted to the company's shareholders' meeting for consideration.

CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.Jordan sold his Chicago mansion for $9.5 million, with a price reduction of 67%. According to Beiqing Sports, Michael Jordan, a famous former American professional basketball player, sold his manor mansion on the outskirts of Chicago for $9.5 million. In 2012, the public price of this mansion was $29 million. After 12 years of listing, the price was reduced by 67% and it was finally sold.CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.

Goldman Sachs lowered the UK's GDP growth forecast for 2024 from the previous 1.2% to 1.0%.Baiyun Airport: The passenger throughput in the first November increased by 21.16% year-on-year. Baiyun Airport (600004) released the November production and operation data express on the evening of December 13th, and Baiyun Airport took 43,637 flights (sorties) in November, up by 12.94% year-on-year. Passenger throughput was 6,504,400 person-times, up by 19.94% year-on-year; The cargo and mail throughput was 212,100 tons, a year-on-year increase of 5.68%. Baiyun Airport took off and landed 465,983 sorties from January to November, up 12.05% year-on-year; The passenger throughput was 69.6674 million person-times, up by 21.16% year-on-year; The cargo and mail throughput was 2,161,300 tons, up 18.12% year-on-year.On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)